Scientists of the Institute of Medical Virology in Frankfurt am Main (Germany) conducted a study of the antiviral effect of the drug against SARS-COV-2 virus in a cell model. The drug was tested on human cells infected with SARS-COV-2 Enisamium showed a good effect. This was the reason for starting clinical trials of the drug in Ukraine.
Upon successful completion of the tests, Amizon will be available in all countries where Farmak is present.
Clinical trials will last several months.
“Amizon” as an effective drug for the treatment of influenza and other SARS is already bought by patients in 11 countries – including Belarus, Kazakhstan, Uzbekistan and others.
